BiotechTube

Ruxolitinib continuous therapy

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bone Marrow Fibrosis

Conditions

Bone Marrow Fibrosis

Trial Timeline

Dec 21, 2016 → Oct 7, 2025

NCT ID
NCT03333187

About Ruxolitinib continuous therapy

Ruxolitinib continuous therapy is a phase 2 stage product being developed by Novartis for Bone Marrow Fibrosis. The current trial status is active. This product is registered under clinical trial identifier NCT03333187. Target conditions include Bone Marrow Fibrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03333187Phase 2Active

Competing Products

20 competing products in Bone Marrow Fibrosis

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
TacrolimusAstellas PharmaPhase 2
52
TacrolimusAstellas PharmaPhase 2
52
MerestinibEli LillyPhase 1
33
FORTEO + PlaceboEli LillyPhase 1
33
Arzoxifene + PlaceboEli LillyPhase 3
77
TanezumabEli LillyPhase 3
77
Anastrozole + TamoxifenAstraZenecaPhase 3
77
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
77
Zoledronic acidNovartisPhase 3
77
Zoledronic acid + LetrozoleNovartisPhase 3
77
Zoledronic acidNovartisPhase 3
77
NilotinibNovartisPhase 1
33
Reclast (ZOL446, zoledronic acid)NovartisApproved
85
Zoledronic acidNovartisPhase 3
77
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33
zoledronic acidNovartisApproved
85

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85